Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07220642 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide

Study acronym: RENEW 1
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Secondary endpoints: 41 to 27v9
  2. Primary endpoint(s) modified
    • Secondary endpoints: 26 to 41
    • Study sites revised (40)
    v8
  3. Study sites revised (40)v7
  4. Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date: May 26, 2027 to May 11, 2027
    • Study completion date: Jul 14, 2027 to Jun 29, 2027
    • Site details revised at 40 of 40 sites
    v6
  5. Study sites revised (40)v5
Show 3 earlier versionsHide 3 earlier versions
  1. Study sites revised (40)v4
  2. Site details revised at 2 of 40 sitesv3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised at 40 of 40 sites
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Novo Nordisk
268 trials monitored
See 15 trials at risk
Obesity
3,876 trials monitored
See 160 trials at risk
This study will look at how much cagrilintide helps people with overweight or obesity lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide. Participants will either get cagrilintide or placebo. Which treatment participants get is decided by chance. Participants are two times more likely to get cagrilintide than placebo. Like all medicines, the study medicine may have side effects. Possible side effects will be followed carefully during the study. For each participant, the study will last for about 1 year and 6 months.
Trial Details
NCT Number NCT07220642
Lead Sponsor Novo Nordisk A/S
Conditions
(from sponsor)		 Obesity, Overweight
Related terms Obesity, Overweight
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov